MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
Clinical trial NCT04649359 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04649359
- Sponsor
- Pfizer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-02-02
- Primary completion
- 2022-06-17
- Enrollment
- 187
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.